CGAS and hepatocellular carcinoma: Lv et al. suggested that targeting the protein gasdermin D (GSDMD) in HCC cells can sensitize them to anti-PD-1 therapy, which was achieved by activating the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS) pathway and downregulating PD-L1 expression [160].